Hypertension
The Hypertension pipeline: 47 tracked drugs, 3 approved for this indication.
3 approved / phase 417 Phase 39 Phase 21 Phase 1/29 Phase 18 preclinical / unstaged
Compare the share prices of listed companies in Hypertension →
Total attributable cost
$347.4B
$2,759/patient
Drug spend
$34.5B
$274/patient
All severities (2017 ACC/AHA threshold) · US
The Hypertension pipeline
Key trial results for every approved and late-stage drug: Hypertension results by drug.